Literature DB >> 25299500

Secondary prevention of coronary artery disease in contemporary clinical practice.

Piotr Jankowski1, Danuta Czarnecka, Renata Wolfshaut-Wolak, Radosław Łysek, Anna Łukaszewska, Piotr Bogacki, Janusz Grodecki, Ewa Mirek-Bryniarska, Jadwiga Nessler, Piotr Podolec, Kalina Kawecka-Jaszcz, Andrzej Pająk.   

Abstract

BACKGROUND: The highest priority in preventive cardiology was given to patients with established coronary artery disease (CAD). The aim of the study was to assess the implementation of guidelines for secondary prevention in everyday clinical practice by evaluating control of the main risk factors and the cardioprotective medication prescription rates for patients, following their hospitalization for CAD.
METHODS: Five hospitals with cardiology departments serving the city and its surround-ing districts in southern part of Poland participated in the study. Consecutive patients aged ≤ 80 years, hospitalized from January 1 2010 to April 31 2012 due to an acute coronary syndrome or for a myocardial revascularization procedure were recruited and interviewed 6-18 months after hospitalization.
RESULTS: The medical records of 595 patients (mean age: 62.8 ± 9.0 years, 397 men and 198 women) were reviewed and included in the analyses. Proportions of medical records with available information on risk factors were high with the exception of total cholesterol levels as well as weight and height measurements, which were available in less than 80% of the hospital records. The prescription rate at discharge for antiplatelets was 99%, beta-blockers (BB)--85%, angiotensin converting enzyme inhibitors (ACEI) or sartans--85%, and lipid-lowering drugs--94%. Patients scheduled for coronary artery bypass grafting were significantly less often prescribed BB, ACEI or sartans, and lipid-lowering drugs. The proportion of patients with high blood pressure (≥ 140/90 mm Hg) 6-18 months after hospitalization was 47%, with high LDL cholesterol level (≥ 1.8 mmol/L) 73%, and with a high HbA1c level (≥ 7.0%) 14%, whereas 20% of participants were smokers and 80% were overweight. The proportion of patients taking an antiplatelet agent 6-18 months after hospitalization was 90%, BB--82%, ACEI--or sartan 78%, and lipid-lowering drug--82%. Overall, 33.9% of the study participants declared that they had been advised to participate in a rehabilitation/secondary prevention program following their hospitalization and 30.5% participated in a rehabilitation/secondary prevention program. However, only 28.2% took part in at least half of the planned sessions. Using a multivariate analysis we showed that, in general, risk factors control and the prescription rates of cardioprotective medications were related to the patients' age, education, and participation in a rehabilitation/secondary prevention program following their hospitalization due to CAD.
CONCLUSIONS: Our data provide evidence that there is a considerable potential for further reduction of cardiovascular risk in CAD patients. Our results suggest that increasing patient participation rates in rehabilitation/secondary prevention programs may improve the implementation of the secondary prevention.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25299500     DOI: 10.5603/CJ.a2014.0066

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  10 in total

1.  Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey.

Authors:  Piotr Jankowski; Dariusz A Kosior; Paweł Sowa; Karolina Szóstak-Janiak; Paweł Kozieł; Agnieszka Krzykwa; Emilia Sawicka; Maciej Haberka; Małgorzata Setny; Karol Kamiński; Zbigniew Gąsior; Aldona Kubica; Dirk De Bacquer; Guy De Backer; Kornelia Kotseva; David Wood; Andrzej Pająk; Danuta Czarnecka
Journal:  Cardiol J       Date:  2020-05-21       Impact factor: 2.737

2.  Practice setting and secondary prevention of coronary artery disease.

Authors:  Piotr Jankowski; Danuta Czarnecka; Leszek Badacz; Piotr Bogacki; Jacek S Dubiel; Janusz Grodecki; Tomasz Grodzicki; Janusz Maciejewicz; Ewa Mirek-Bryniarska; Jadwiga Nessler; Wiesław Piotrowski; Piotr Podolec; Wanda Śmielak-Korombel; Wiesława Tracz; Kalina Kawecka-Jaszcz; Andrzej Pająk
Journal:  Arch Med Sci       Date:  2017-01-19       Impact factor: 3.318

3.  Knowledge and Prevalence of Risk Factors for Coronary Artery Disease in Patients after Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting.

Authors:  Mikołaj Matysek; Krzysztof Wójcicki; Tomasz Tokarek; Artur Dziewierz; Tomasz Rakowski; Stanisław Bartuś; Dariusz Dudek
Journal:  Healthcare (Basel)       Date:  2022-06-20

4.  Influence of Risk Factors on Exercise Tolerance in Patients after Myocardial Infarction-Early Cardiac Rehabilitation in Poland.

Authors:  Aleksandra Bryndal; Sebastian Glowinski; Agnieszka Grochulska
Journal:  J Clin Med       Date:  2022-09-23       Impact factor: 4.964

5.  PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.

Authors:  Krzysztof Jaworski; Piotr Jankowski; Dariusz A Kosior
Journal:  Arch Med Sci       Date:  2017-01-19       Impact factor: 3.318

6.  Managed Care after Acute Myocardial Infarction (KOS-zawał) reduces major adverse cardiovascular events by 45% in 3-month follow-up - single-center results of Poland's National Health Fund program of comprehensive post-myocardial infarction care.

Authors:  Krystian Wita; Andrzej Kułach; Marcin Wita; Maciej T Wybraniec; Katarzyna Wilkosz; Mateusz Polak; Monika Matla; Łukasz Maciejewski; Joanna Fluder; Barbara Kalańska-Łukasik; Tomasz Skowerski; Szymon Gomułka; Krzysztof Szydło
Journal:  Arch Med Sci       Date:  2019-06-06       Impact factor: 3.318

7.  The Efficacy of Inpatient vs. Home-Based Physiotherapy Following Coronary Artery Bypass Grafting.

Authors:  Aleksandra Szylińska; Mariusz Listewnik; Iwona Rotter; Aleksandra Rył; Katarzyna Kotfis; Krzysztof Mokrzycki; Ewelina Kuligowska; Paweł Walerowicz; Mirosław Brykczyński
Journal:  Int J Environ Res Public Health       Date:  2018-11-17       Impact factor: 3.390

8.  Patient counselling service with the use of pictograms as the example of pharmacist intervention to improving compliance and medicine safety.

Authors:  Piotr Merks; Damian Świeczkowski; Marcin Balcerzak; Urszula Religioni; Ewelina Drelich; Jerzy Krysiński; Dagmara Hering; Miłosz Jaguszewski
Journal:  Cardiol J       Date:  2021-02-26       Impact factor: 2.737

Review 9.  The plague of unexpected drug recalls and the pandemic of falsified medications in cardiovascular medicine as a threat to patient safety and global public health: A brief review.

Authors:  Damian Świeczkowski; Szymon Zdanowski; Piotr Merks; Łukasz Szarpak; Régis Vaillancourt; Milosz J Jaguszewski
Journal:  Cardiol J       Date:  2020-12-21       Impact factor: 2.737

10.  Cardiac Rehabilitation in Real Life.

Authors:  Piotr Jankowski; Andrzej Pajak; Radoslaw Lysek; Anna Lukaszewska; Renata Wolfshaut-Wolak; Piotr Bogacki; Janusz Grodecki; Ewa Mirek-Bryniarska; Jadwiga Nessler; Piotr Podolec; Kalina Kawecka-Jaszcz; Danuta Czarnecka
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.